Fri, Sep 19, 2014, 1:44 PM EDT - U.S. Markets close in 2 hrs 16 mins


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

ries123 8 posts  |  Last Activity: Sep 5, 2014 10:02 AM Member since: Jun 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Insmed Announces Multiple Clinical and Scientific Presentations at European Respiratory Society's International Congress 2014
    Introduces INS-1009 (Treprostinil) for the Treatment of Pulmonary Arterial Hypertension

    BRIDGEWATER, NJ -- (Marketwired) -- 09/03/14 -- Insmed Incorporated (NASDAQ: INSM) announces that the Company's novel inhalation technologies for the treatment of orphan pulmonary diseases will be highlighted in a variety of clinical and scientific presentations at the European Respiratory Society's (ERS) International Congress 2014, taking place September 6-10, 2014 at the Internationales Congress Center München in Munich, Germany.

    There will be several presentations regarding the Company's lead product ARIKAYCE™, or liposomal amikacin for inhalation delivered by an investigational eFlow® Nebulizer System (PARI Pharma GmbH), for the treatment of both nontuberculous mycobacteria lung infections (NTM) and Pseudomonas aeruginosa in cystic fibrosis patients. In addition, the Company will present several posters regarding INS-1009 (treprostinil), the Company's novel inhalation formulation of a proven prostacyclin for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

    Insmed has applied its product design, drug development and sustained-release formulation expertise to advance INS-1009 with the goal of addressing current limitations of inhaled prostacyclin therapies in the treatment of PAH. INS-1009 is expected to be delivered once-daily via inhalation. It is designed to provide consistent, effective drug levels and may also reduce the acute systemic effects of current treatment options.

    Sentiment: Strong Buy

  • Trying to scare somebody.. ? 50 shares at $ 19.56 Pre-market (08:45:43 AM)

    Sentiment: Strong Buy

  • ries123 ries123 Jul 23, 2014 9:29 AM Flag

    As far as I'm concerned Insmed will top Puma... but it still is a long wait. Every day at 14.08 hrs (CET) I stare at my mailbox, because that is usually the time when a PR hits the wires pre-market..

    Sentiment: Strong Buy

  • BRIDGEWATER, NJ -- (Marketwired) -- 09/05/14 -- Insmed Incorporated (NASDAQ: INSM), announces that Company management will participate at the upcoming Rodman & Renshaw Annual Global Investment Conference taking place September 8 - 10, 2014 at the New York Palace Hotel.

    Sentiment: Strong Buy

  • ries123 ries123 Jul 23, 2014 9:54 AM Flag

    No comparison but we're doing alright too: $18,13 (+$0.43) + 2,43%

    Sentiment: Strong Buy

  • Reply to

    Price target raised from $30 to $51. Really!!!!

    by mengyhuynh Jun 19, 2014 3:40 PM
    ries123 ries123 Jun 19, 2014 3:49 PM Flag

    Freakin' schizophrenic..

    Sentiment: Strong Buy

  • ries123 by ries123 Jul 21, 2014 7:32 AM Flag

    do we hear something substantial from Insmed ? I've read here that something is cooking (partnership, buyout, merger and, in general, 'PR's are looming') but unfortunately untill now we have the too well-known radio silence..

    Sentiment: Strong Buy

  • Reply to

    Roche pays $8.3B for Intermune

    by b_leaguered Aug 24, 2014 9:31 PM
    ries123 ries123 Aug 25, 2014 9:41 AM Flag

    For now it has a positive influence on the stock price.. up we go !

    Sentiment: Strong Buy

13.10-0.08(-0.61%)1:43 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.